ArticleNeuropsychiatric disease and treatment2010
Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.
Article in Neuropsychiatric disease and treatment, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Guideline
- An integrative neuropharmacological review of Huntington's disease challenges and the role of novel formulations in addressing pharmacological‒pharmaceutical limitations.Frontiers in pharmacology · 2026Review
- Revolutionizing Huntington's Disease Treatment: Breakthroughs in AAV-Mediated Gene Therapy.Cells · 2025Review
- Application of Casein Micelles for Targeting Huntington's Disease in Experimental Zebrafish Model.Molecular neurobiology · 2025Article
- Review
- Effect of Capsaicin on 3-NP-Induced Neurotoxicity: A Pre-Clinical Study.Neurochemical research · 2024Article
- WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective.Diseases (Basel, Switzerland) · 2023Review
- Effects of the dopamine depleting agent tetrabenazine on detailed temporal parameters of effort-related choice responding.Journal of the experimental analysis of behavior · 2022Article
- Application of Cognitive Bias Testing in Neuropsychiatric Disorders: A Mini-Review Based on Animal Studies.Frontiers in behavioral neuroscience · 2022Review
- Vigor, Effort-Related Aspects of Motivation and Anhedonia.Current topics in behavioral neurosciences · 2022Review
- A Brief Review on the Role of Vesicular Monoamine TransporterIranian journal of child neurology · 2021Review
- Behavioral and dopamine transporter binding properties of the modafinil analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and enhancement of progressive ratio responding.Psychopharmacology · 2020Article
- The dopamine depleting agent tetrabenazine alters effort-related decision making as assessed by mouse touchscreen procedures.Psychopharmacology · 2020Article
- Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians.Neuropsychological rehabilitation · 2020Article
- Synthesis of Tetrabenazine and Its Derivatives, Pursuing Efficiency and Selectivity.Molecules (Basel, Switzerland) · 2020Review
- The Novel Atypical Dopamine Uptake InhibitorFrontiers in pharmacology · 2019Article
- The Psychopharmacology of Effort-Related Decision Making: Dopamine, Adenosine, and Insights into the Neurochemistry of Motivation.Pharmacological reviews · 2018Review
- Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.Journal of Huntington's disease · 2018Review
- Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression.Frontiers in pharmacology · 2018Review
- Dopamine, Effort-Based Choice, and Behavioral Economics: Basic and Translational Research.Frontiers in behavioral neuroscience · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington disease (HD) is a dominantly inherited progressive neurological disease characterized by chorea, an involuntary brief movement that tends to flow between body regions. HD is typically diagnosed based on clinical findings in the setting of a family history and may be confirmed with genetic testing. Predictive testing is available to those at risk, but only experienced clinicians should perform the counseling and testing. Multiple areas of the brain degenerate mainly involving the neurotransmitters dopamine, glutamate, and γ-aminobutyric acid. Although pharmacotherapies theoretically target these neurotransmitters, few well-conducted trials for symptomatic or neuroprotective interventions yielded positive results. Tetrabenazine (TBZ) is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects. Some newer antipsychotic agents, such as olanzapine and aripiprazole, may have adequate efficacy with a more favorable adverse-effect profile than older antipsychotic agents for treating chorea and psychosis. This review will address the epidemiology and diagnosis of HD as background for understanding potential pharmacological treatment options. Because TBZ is the only US Food and Drug Administration-approved medication in the United States for HD, the focus of this review will be on its pharmacology, efficacy, safety, and practical uses. There are no current treatments to change the course of HD, but education and symptomatic therapies can be effective tools for clinicians to use with patients and families affected by HD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.